Trial Profile
The effect of Lansoprazole in the prevention of osteonecrosis of the femoral head in patients with immune diseases treated corticosteroid
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Sep 2019
Price :
$35
*
At a glance
- Drugs Lansoprazole (Primary) ; Lansoprazole (Primary)
- Indications Osteonecrosis
- Focus Therapeutic Use
- 08 Sep 2019 Status changed from recruiting to discontinued.
- 01 Sep 2015 New trial record